2026-08-23 · saxenda, wegovy, liraglutide, semaglutide, glp-1, brand comparison, STEP-8

Are Saxenda and Wegovy made by the same company?

Yes. Both are Novo Nordisk GLP-1 receptor agonists FDA-approved for chronic weight management. Saxenda is liraglutide 3.0 mg injected once daily; Wegovy is semaglutide 2.4 mg injected once weekly. Semaglutide is the successor molecule with roughly a one-week half-life versus liraglutide's ~13 hours, which is why one is dosed daily and the other weekly. The manufacturer, distribution, and prior-authorization pathways are largely the same.

Is Wegovy really twice as effective as Saxenda?

In the STEP-8 head-to-head trial (Rubino 2022, JAMA), 338 adults were randomized to semaglutide 2.4 mg, liraglutide 3.0 mg, or placebo for 68 weeks on identical intensive lifestyle counseling. Semaglutide produced −15.8% mean weight loss versus −6.4% on liraglutide and −1.9% on placebo — roughly 2.5x more loss on Wegovy. 70.9% of Wegovy patients hit ≥10% loss compared with 25.6% on Saxenda. Individual response varies, but the trial-level answer is yes.

Which has worse side effects?

The side-effect families are identical (nausea, diarrhea, constipation, vomiting), and headline rates are broadly comparable at maximum dose. Trial data run Wegovy slightly higher on GI events (nausea ~44% vs ~39%, vomiting ~24% vs ~16%), but STEP-8 discontinuation-for-adverse-events was almost identical (3.2% semaglutide vs 3.1% liraglutide). Practically, Saxenda's daily dose distributes GI symptoms across the week, while Wegovy delivers a 24–48-hour post-injection peak. Some patients tolerate one but not the other.

Can I switch from Saxenda to Wegovy?

Yes, and it is common when Saxenda is not delivering, when insurance shifts, or when the patient wants the weekly schedule. Discontinue Saxenda after the last daily dose and start Wegovy at its lowest step (0.25 mg weekly), then follow the standard 16–20-week titration. Do not skip steps — semaglutide's own titration exists to manage GI tolerability, and jumping to a higher starting dose produces avoidable nausea. Expect a temporary period of GI adjustment for a few weeks after each dose escalation.

Is Saxenda cheaper than Wegovy?

The cash list price is essentially the same — roughly $1,349 per month for either brand — because both are Novo Nordisk products at premium GLP-1 pricing. Manufacturer cash-pay programs differ: NovoCare offers a Wegovy cash-pay route around $499/month for eligible patients, and a Saxenda NovoCare cash-pay program around $530/month. The larger 2026 shift is the arrival of generic liraglutide 3.0 mg (first approved Aug 2024), which can bring self-pay well below Wegovy's floor as launch pricing settles.

Is Saxenda still worth taking now that Wegovy exists?

For most adults starting today, Wegovy is the default choice. Saxenda remains rational in three scenarios: (1) a plan formulary requires it first under step therapy; (2) a patient genuinely prefers a daily injection or tolerates the smaller per-dose GI hit better than the weekly peak; (3) generic liraglutide 3.0 mg brings the cash-pay cost meaningfully below Wegovy for a self-pay patient. Adolescent-only-Saxenda is no longer a reason since Wegovy's Dec 2022 adolescent approval.

Can teens use Saxenda or Wegovy?

Both are FDA-approved for adolescents 12+ with obesity. Saxenda's adolescent indication came first (SCALE Adolescent, Kelly 2020 NEJM: −4.29% BMI vs +0.5% placebo at 56 weeks; FDA extension Dec 2020). Wegovy's adolescent approval followed in Dec 2022 on the strength of STEP-TEENS (Weghuber 2022 NEJM: −16.1% BMI vs +0.6% placebo at 68 weeks). Adolescent efficacy now favors semaglutide as strongly as adult data does — the historical 'Saxenda for teens' argument no longer holds.

Is there a generic liraglutide (Saxenda) in 2026?

Yes. Liraglutide's US patent protection expired in December 2023, and the FDA approved the first generic liraglutide 3.0 mg from Teva in August 2024. Additional generic filings have followed. Launch pricing is still settling in 2026, but the practical effect is that generic liraglutide 3.0 mg can now be dispensed at a lower cash-pay cost than branded Saxenda and materially below Wegovy — one of the strongest new reasons to consider liraglutide over semaglutide for a self-pay patient without insurance coverage.

Saxenda vs Wegovy

The one-sentence answer

Wegovy (semaglutide 2.4 mg weekly) beats Saxenda (liraglutide 3.0 mg daily) on both weight loss and injection frequency in the STEP-8 head-to-head — roughly −15.8% vs −6.4% at 68 weeks — but Saxenda persists on the market because insurers still place it ahead of Wegovy under step therapy, because a minority of patients prefer daily dosing, and because generic liraglutide 3.0 mg (first approved Aug 2024) is now the cheapest FDA-approved GLP-1 on a self-pay label. Adolescent use is no longer a Saxenda-only argument — Wegovy has carried a 12+ indication since December 2022.

For the same-class weekly-vs-weekly question, see Wegovy vs Zepbound. For the diabetes-labeled semaglutide sibling, see Ozempic vs Wegovy. For the fuller four-brand walkthrough, see GLP-1 medications compared.

What each drug is

Saxenda is liraglutide dosed at 3.0 mg subcutaneously once daily, made by Novo Nordisk. It was the first GLP-1 receptor agonist FDA-approved specifically for chronic weight management, approved in December 2014 for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity. The adolescent 12+ indication was added in December 2020 on the strength of the SCALE Adolescent trial. Liraglutide shares 97% amino-acid homology with native GLP-1 and has a serum half-life of roughly 13 hours, which is why once-daily injection is required.

Wegovy is semaglutide dosed at 2.4 mg subcutaneously once weekly, also made by Novo Nordisk. It received obesity approval in June 2021 (STEP-1), an adolescent 12+ extension in December 2022 (STEP-TEENS), and a cardiovascular-risk-reduction indication in March 2024 for adults with established CVD and obesity/overweight (SELECT). Semaglutide shares 94% homology with native GLP-1 and carries structural modifications that extend its half-life to roughly one week — the pharmacology behind weekly dosing and, along with slightly higher receptor affinity, most of its efficacy edge over liraglutide.

Both drugs share the same GLP-1 mechanism — receptor agonism at hypothalamic satiety neurons, slowed gastric emptying, and glucose-dependent insulin secretion. Semaglutide is the successor molecule.

Head-to-head efficacy — STEP-8 (Rubino 2022 JAMA)

STEP-8 is the only randomized trial that directly compared Saxenda and Wegovy at their maximum doses. Rubino and colleagues randomized 338 adults with obesity and without diabetes to semaglutide 2.4 mg weekly, liraglutide 3.0 mg daily, or matching placebos over 68 weeks, on top of identical intensive behavioral counseling in a US ambulatory setting.

• Mean total-body weight loss: −15.8% on semaglutide vs −6.4% on liraglutide vs −1.9% on placebo.
• ≥10% weight loss response: 70.9% on semaglutide vs 25.6% on liraglutide.
• ≥15% weight loss response: 55.6% on semaglutide vs 12.6% on liraglutide.
• Discontinuation for adverse events: 3.2% semaglutide vs 3.1% liraglutide — essentially identical.

This is the strongest evidence a patient will see on the pair. The 2.5-fold weight-loss gap is not a cross-trial inference — it is a direct randomized head-to-head at the doses each drug is actually prescribed at. Individual response still varies substantially, and a significant minority of patients on Saxenda hit ≥10% loss while a significant minority on Wegovy do not.

Registrational-trial efficacy — for context

For readers who want the individual-drug numbers behind each label:

• SCALE Obesity and Prediabetes (Pi-Sunyer 2015, NEJM, n = 3,731, 56 weeks): liraglutide 3.0 mg −8.0% vs placebo −2.6% in adults with obesity.
• STEP-1 (Wilding 2021, NEJM, n = 1,961, 68 weeks): semaglutide 2.4 mg −14.9% vs placebo −2.4% in adults with obesity without diabetes.
• SCALE Adolescent (Kelly 2020, NEJM, n = 251, 56 weeks): liraglutide 3.0 mg −4.29% BMI vs placebo +0.5% BMI in ages 12–17.
• STEP-TEENS (Weghuber 2022, NEJM, n = 201, 68 weeks): semaglutide 2.4 mg −16.1% BMI vs placebo +0.6% BMI in ages 12–17.

The −8.0% vs −14.9% adult cross-trial gap tracks the STEP-8 head-to-head, and the adolescent trials show semaglutide’s efficacy edge is at least as large in ages 12–17 as it is in adults. The historical “Saxenda is the only GLP-1 for teens” argument no longer holds after the Wegovy adolescent extension in December 2022.

Side-effect comparison table

Common GI side effects at maximum dose, drawn primarily from SCALE Obesity (Saxenda) and STEP-1 (Wegovy), with STEP-8 confirmatory data:

A practical note the table cannot show: daily-dose GI symptoms tend to be more evenly distributed and shorter-duration than the once-weekly semaglutide 24–48-hour post-injection peak. Some patients who cannot tolerate Wegovy’s weekly wave do tolerate Saxenda’s daily cadence, and vice versa. Both drugs share the same class-level serious risks — the boxed warning for medullary thyroid C-cell tumors (rodent data; contraindicated in personal or family history of MTC or MEN2), uncommon pancreatitis, gallbladder disease (particularly with rapid loss), and dehydration-related acute kidney injury from persistent vomiting or diarrhea. For the class-wide titration playbook, see the tolerability guidance in Ozempic side effects.

Cost and access in 2026

Cash and insurance economics for the two brands in 2026, in US dollars:

Saxenda’s brand list price is the same as Wegovy but its cash-pay lever is smaller — the meaningful 2026 shift is on the generic-liraglutide side. Semaglutide remains patent-protected until the late 2020s, so there is no equivalent generic Wegovy route. For insured patients, prior-authorization criteria are nearly identical for both brands, and the after-savings-card copay lands in the same $25–$100 band. For the fuller payer walkthrough — telehealth bundles, UK NHS and private-clinic pricing, savings-card mechanics — see GLP-1 cost and insurance coverage.

Injection experience — daily vs weekly

Saxenda ships in a 6 mg/mL multi-dose pen delivering up to 3.0 mg per day, with roughly a month of full doses per pen. Titration steps every week: 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg, full titration in 5 weeks. Inject subcutaneously in the abdomen, thigh, or upper arm at roughly the same time each day; timing relative to meals does not matter.

Wegovy ships in single-dose weekly pens, one injection per week on the same day. Titration steps every 4 weeks: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, full titration in 16–20 weeks. Same injection sites, same subcutaneous depth. Missing a dose by more than 2 weeks can prompt a restart at the prior step per prescribing information.

Adherence in the real world favors weekly. Randomized trials show only small daily-vs-weekly differences (roughly 5 percentage points at 1 year), but real-world persistence data lean harder on weekly dosing: the Wharton 2019 Canadian cohort (Current Medical Research and Opinion) and Weiss 2023 (Diabetes, Obesity and Metabolism, 12-month persistence for semaglutide vs liraglutide) both show weekly-agent persistence pulling ahead by 6–12 months. Daily injection burden is the single most-cited reason for Saxenda discontinuation in cohort data.

When Saxenda still makes sense

Three scenarios where Saxenda is a rational first choice in 2026:

• The plan formulary forces it first under step therapy. Try it, and escalate to Wegovy if intolerance or inadequate response persists at the FDA week-16 mark (≥4% loss required to justify continuing). Step-therapy failures create the documentation payers require for Wegovy authorization.
• The patient genuinely prefers daily dosing. Unusual but real. Some patients build daily injections into a morning routine more easily than a Sunday-only ritual, and some find the smaller per-dose GI hit easier to tolerate than semaglutide’s weekly 24–48-hour peak.
• Pregnancy planning where a shorter washout matters. Both drugs are class-contraindicated in pregnancy and should be discontinued at least 2 months preconception per Wegovy labeling. Liraglutide’s ~13-hour half-life gives a much shorter functional washout than semaglutide’s ~1-week half-life if the drug needs to be stopped quickly for an unplanned pregnancy or a new contraindication.

Adolescent use is no longer Saxenda-only. Wegovy carries a 12+ indication since December 2022, and the STEP-TEENS BMI reduction (−16.1% vs +0.6% placebo) is larger than SCALE Adolescent (−4.29% vs +0.5%). If the family and clinician are comfortable with a weekly injection, Wegovy is now the more evidence-supported adolescent choice.

What both do NOT do

• Not a substitute for a calorie deficit. Both trials embedded structured behavioral counseling and a modest calorie-deficit target in every arm. Real-world outcomes without that scaffolding land several percentage points lower.
• Not FDA-approved for type 2 diabetes. Victoza (liraglutide 1.8 mg) is the T2D-labeled liraglutide sibling; Ozempic (semaglutide 0.5–2.0 mg) is the T2D-labeled semaglutide sibling. If you have T2D, the covered pathway is almost always the T2D-indication brand.
• Not legally available as compounded formulations in 2026. The semaglutide shortage was resolved in October 2024, ending the FDA-shortage carve-out that had permitted 503A compounded semaglutide. Liraglutide is now off-patent (US patent expired December 2023) and the FDA approved the first generic liraglutide 3.0 mg from Teva in August 2024 — which makes the compounding pathway moot for liraglutide because a legal, cheaper generic exists.
• Not head-to-head tested against Zepbound, Mounjaro, or retatrutide. STEP-8 is the definitive Saxenda-vs-Wegovy comparison; SURMOUNT-5 is the definitive Wegovy-vs-Zepbound comparison. No published head-to-head yet pits either drug against tirzepatide or the next-generation triple agonists — see retatrutide vs tirzepatide and next generation weight loss drugs for what is coming.

Practical 2026 bottom line

Wegovy is the default first choice for both adults and adolescents starting therapy today. Saxenda is rational when insurance forces it first under step therapy, when a patient genuinely prefers daily dosing or tolerates the smaller per-dose GI hit better, or when the newly approved generic liraglutide 3.0 mg brings cash-pay well below Wegovy’s floor. If step therapy or a cost change pushes you from Saxenda up to Wegovy — the generational-upgrade switch this article most often triggers — how to switch between GLP-1 medications covers the specific protocol (stop Saxenda the day of your first Wegovy dose, restart Wegovy at 0.25 mg, do not skip titration). The rest of the site walks the neighboring decisions: Wegovy for weight loss and Saxenda for weight loss cover each drug in depth, Wegovy vs Zepbound handles the next comparison up the ladder, and GLP-1 medications compared puts all four brand names side-by-side.

Frequently asked questions

Are Saxenda and Wegovy made by the same company? Yes. Both are Novo Nordisk GLP-1 receptor agonists FDA-approved for chronic weight management. Saxenda is liraglutide 3.0 mg injected once daily; Wegovy is semaglutide 2.4 mg injected once weekly. Semaglutide is the successor molecule with roughly a one-week half-life versus liraglutide’s ~13 hours, which is why one is dosed daily and the other weekly. The manufacturer, distribution, and prior-authorization pathways are largely the same.

Is Wegovy really twice as effective as Saxenda? In the STEP-8 head-to-head trial (Rubino 2022, JAMA), 338 adults were randomized to semaglutide 2.4 mg, liraglutide 3.0 mg, or placebo for 68 weeks on identical intensive lifestyle counseling. Semaglutide produced −15.8% mean weight loss versus −6.4% on liraglutide and −1.9% on placebo — roughly 2.5x more loss on Wegovy. 70.9% of Wegovy patients hit ≥10% loss compared with 25.6% on Saxenda. Individual response varies, but the trial-level answer is yes.

Which has worse side effects? The side-effect families are identical (nausea, diarrhea, constipation, vomiting), and headline rates are broadly comparable at maximum dose. Trial data run Wegovy slightly higher on GI events (nausea ~44% vs ~39%, vomiting ~24% vs ~16%), but STEP-8 discontinuation-for-adverse-events was almost identical (3.2% semaglutide vs 3.1% liraglutide). Practically, Saxenda’s daily dose distributes GI symptoms across the week, while Wegovy delivers a 24–48-hour post-injection peak. Some patients tolerate one but not the other.

Can I switch from Saxenda to Wegovy? Yes, and it is common when Saxenda is not delivering, when insurance shifts, or when the patient wants the weekly schedule. Discontinue Saxenda after the last daily dose and start Wegovy at its lowest step (0.25 mg weekly), then follow the standard 16–20-week titration. Do not skip steps — semaglutide’s own titration exists to manage GI tolerability, and jumping to a higher starting dose produces avoidable nausea. Expect a temporary period of GI adjustment for a few weeks after each dose escalation.

Is Saxenda cheaper than Wegovy? The cash list price is essentially the same — roughly $1,349 per month for either brand — because both are Novo Nordisk products at premium GLP-1 pricing. Manufacturer cash-pay programs differ: NovoCare offers a Wegovy cash-pay route around $499/month for eligible patients, and a Saxenda NovoCare cash-pay program around $530/month. The larger 2026 shift is the arrival of generic liraglutide 3.0 mg (first approved Aug 2024), which can bring self-pay well below Wegovy’s floor as launch pricing settles.

Is Saxenda still worth taking now that Wegovy exists? For most adults starting today, Wegovy is the default choice. Saxenda remains rational in three scenarios: (1) a plan formulary requires it first under step therapy; (2) a patient genuinely prefers a daily injection or tolerates the smaller per-dose GI hit better than the weekly peak; (3) generic liraglutide 3.0 mg brings the cash-pay cost meaningfully below Wegovy for a self-pay patient. Adolescent-only-Saxenda is no longer a reason since Wegovy’s Dec 2022 adolescent approval.

Can teens use Saxenda or Wegovy? Both are FDA-approved for adolescents 12+ with obesity. Saxenda’s adolescent indication came first (SCALE Adolescent, Kelly 2020 NEJM: −4.29% BMI vs +0.5% placebo at 56 weeks; FDA extension Dec 2020). Wegovy’s adolescent approval followed in Dec 2022 on the strength of STEP-TEENS (Weghuber 2022 NEJM: −16.1% BMI vs +0.6% placebo at 68 weeks). Adolescent efficacy now favors semaglutide as strongly as adult data does — the historical “Saxenda for teens” argument no longer holds.

Is there a generic liraglutide (Saxenda) in 2026? Yes. Liraglutide’s US patent protection expired in December 2023, and the FDA approved the first generic liraglutide 3.0 mg from Teva in August 2024. Additional generic filings have followed. Launch pricing is still settling in 2026, but the practical effect is that generic liraglutide 3.0 mg can now be dispensed at a lower cash-pay cost than branded Saxenda and materially below Wegovy — one of the strongest new reasons to consider liraglutide over semaglutide for a self-pay patient without insurance coverage.

How this article was researched

This article draws on the STEP-8 head-to-head trial (Rubino 2022, JAMA), the SCALE Obesity and Prediabetes trial (Pi-Sunyer 2015, NEJM), the STEP-1 pivotal semaglutide trial (Wilding 2021, NEJM), the SCALE Adolescent trial (Kelly 2020, NEJM), the STEP-TEENS adolescent semaglutide trial (Weghuber 2022, NEJM), FDA prescribing information for Saxenda and Wegovy, the FDA approval notice for generic liraglutide 3.0 mg (Teva, August 2024), the FDA Drug Shortage database, and publicly available Novo Nordisk cash-pay program details. Coverage and pricing details reflect 2026 US commercial and Medicare Part D norms and will move; confirm specific numbers with your insurer, clinician, or manufacturer before making a decision.